Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ifosfamide
Drug ID BADD_D01133
Description Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Indications and Usage Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
Marketing Status approved
ATC Code L01AA06
DrugBank ID DB01181
KEGG ID D00343
MeSH ID D007069
PubChem ID 3690
TTD Drug ID D02TLO
NDC Product Code 10019-925; 57884-0006; 63323-142; 0143-9531; 0338-3991; 15308-0411; 0338-3993; 65124-0001; 0143-9530; 10019-926; 10019-927; 10019-929
UNII UM20QQM95Y
Synonyms Ifosfamide | Isofosfamide | Isophosphamide | Iphosphamide | Iso-Endoxan | Iso Endoxan | Holoxan | NSC-109,724 | NSC 109,724 | NSC109,724 | NSC-109724 | NSC 109724 | NSC109724 | Asta Z 4942
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 3778-73-2
SMILES C1CN(P(=O)(OC1)NCCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malignant neoplasm progression16.16.01.0050.000280%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Necrotising colitis07.08.01.013--Not Available
Lymphatic disorder01.09.01.003--Not Available
Fanconi syndrome acquired20.05.03.012; 14.01.01.0130.000112%Not Available
Drug tolerance decreased08.06.01.0240.000112%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000168%Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000112%Not Available
Growth retardation05.03.02.007; 15.03.05.016; 14.03.02.0310.000112%
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Urine phosphorus increased13.11.01.047--Not Available
Electrocardiogram U-wave abnormality13.14.05.028--Not Available
Brain cancer metastatic17.20.04.001; 16.30.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Major depression19.15.01.003--Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.004--Not Available
Epidermal necrosis23.03.03.035--Not Available
Urine output increased13.13.03.002--Not Available
Recall phenomenon12.02.06.001; 23.03.07.005--
Adverse event08.06.01.0100.000168%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Haematotoxicity12.03.01.025; 01.05.01.0070.000280%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation08.01.05.007; 10.02.01.089--Not Available
Malnutrition14.03.02.004--Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene